MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Section: Diabetes & Endocrinology
Diabetes & Endocrinology

Can an 11β‑HSD1 Inhibitor Improve Prednisolone’s Benefit–Risk Ratio in Polymyalgia Rheumatica? Early Human Trial Suggests Feasibility

MedXY Editorial TeamDec 5, 2025
glucocorticoid toxicityPolymyalgia Rheumatica

Highlights

– Clofutriben, a selective 11β‑HSD1 inhibitor, attenuated many biomarker signals of prednisolone‑related toxicity across tested doses in patients with polymyalgia rheumatica (PMR).

– When combined with clofutriben, prednisolone 10 mg/day produced clinical relapses in some patients; increasing prednisolone to 20–30 mg/day restored symptom control without losing toxicity mitigation.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Safety Profile of SGLT2 Inhibitors in Elderly Patients with Type 2 Diabetes: Insights from a Population-Based Cohort Study

Diabetes & EndocrinologyNov 5, 2026

Acmopatide Shows Promising Glycemic and Weight Control in Overweight Adults with Type 1 Diabetes: Phase 2 Trial Results

Diabetes & EndocrinologyNov 4, 2026

Comparative Effectiveness of Semaglutide versus Dulaglutide or Liraglutide in Hemodialysis Patients with Diabetes

Diabetes & EndocrinologyNov 3, 2026
Loading comments...

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story